Current Literature
In Basic Science

Neurostimulation for Epilepsy:
Do We Know the Best Stimulation Parameters?

Effect of Stimulus Parameters in the Treatment of Seizures by Electrical Stimulation in the Kainate Animal Model.

Preliminary results from animal and clinical studies demonstrate that electrical stimulation of brain structures can reduce seizure frequency in patients with refractory epilepsy. Since most researchers derive stimulation parameters by trial and error, it is unclear what stimulation frequency, amplitude and duration constitutes a set of optimal stimulation parameters for aborting seizure activity in a given patient. In this investigation, we begin to quantify the independent effects of stimulation parameters on electrographic seizures, such that they could be used to develop an efficient closed-loop prosthesis that intervenes before the clinical onset of a seizure and seizure generalization. Biphasic stimulation is manually delivered to the hippocampus in response to a visually detected electrographic seizure. Such focal, responsive stimulation allows for anti-seizure treatment delivery with improved temporal and spatial specificity over conventional open-loop stimulation paradigms, with the possibility of avoiding tissue damage stemming from excessive exposure to electrical stimulation. We retrospectively examine the effects of stimulation frequency (low, medium and high), pulse-width (low and high) and amplitude (low and high) in seizures recorded from 23 kainic acid treated rats. We also consider the effects of total charge delivered and the rate of charge delivery, and identify stimulation parameter sets that induce after-discharges or more seizures. Among the stimulation parameters evaluated, we note 2 major findings. First, stimulation frequency is a key parameter for inhibiting seizure activity; the anti-seizure effect cannot be attributed to only the charge delivered per phase. Second, an after-discharge curve shows that as the frequency and pulse-width of stimulation increases, smaller pulse amplitudes are capable of eliciting an after-discharge. It is expected that stimulation parameter optimization will lead to devices with enhanced treatment efficacies and reduced side-effect profiles, especially when used in conjunction with seizure prediction or detection algorithms in a closed-loop control application.

Commentary
Under ideal circumstances, basic science research precedes clinical adoption of a technology. The reverse path has tended to prevail with deep brain stimulation (DBS) for epilepsy. After pioneering work in use of DBS for psychiatric conditions by Heath and Delgado, the New York neurosurgeon Irving Cooper was the first to use the technology to treat clinical epilepsy (1). Two recent multicenter clinical trials provided Class I evidence of efficacy for direct brain stimulation of anterior thalamus (2) and at the seizure focus (3).

Having been involved in discussions to establish the clinical parameters of stimulation in one of these trials, I can lament the lack of guidance from basic science as to the best stimulation parameters. Variables to be considered are prodigious, including anatomic site of stimulation, pulse width, pulse frequency, delivery as constant current or constant voltage, intensity of stimulation, whether to ramp intensity up over time and if so what time intervals, bipolar local stimulation versus stimulation to a distant reference, initial polarity negative or positive, and cycling of stimulation by a clock setting (how long on and off?) versus continuous stimulation or responsive stimulation (responsive to what?). The combinatorial possibilities are overwhelming, amounting to many thousands of possible choices. For the clinical trials, educated and rather arbitrary guesses were made, locking the protocol into parameters that might be far from optimal. The anterior thalamic DBS study stimulated at 5V, 0.9 ms pulses, at 145 pulses per second, on for 1 minute and off for 5 minutes. Some of the parameters imitated those of pilot trials from Cooper and the Velascos (4). Upper limits to the amount of current per pulse can be derived from studies of stimulation-induced tissue damage (5). Experience with movement disorders, where tremor can be assayed rapidly upon changes of stimulation settings, generated the concept that low-frequency stimulation was less effective than high-frequency. Although stimulation for movement disorders is usually done continuously, experience with intermittent vagus nerve stimulation and the desire to preserve battery life persuaded investigators in the thalamic DBS study to use intermittent stimulation. Respon-
Neurostimulation for Epilepsy

sive neurostimulation is initiated only when an algorithm detects preprogrammed features of the EEG.

Modern neurosurgeons employ stereotactic neurosurgery and neuroimaging to place electrodes with millimeter accuracy. Much less precise, however, is the amount of tissue stimulated by direct brain stimulation leads. Medtronic DBS leads typically comprise four contacts spaced either 0.5 or 1.5 mm apart. Current flow modeling (6) suggests that bipolar stimulation of adjacent contacts distributes current over a smaller area. Bipolar stimulation of leads at the proximal and distal ends of the DBS lead may, in turn, only produce local current flow close to each lead and not across the entire region of interest (personal communication, Mark Rise of Medtronic). A larger region can be stimulated by stimulation with one contact in the brain and another at a distance reference, such as the stimulator case in the chest wall. However, such stimulation may extend beyond the nucleus of interest, particularly if the nucleus is not spherical. Stimulation of adjacent brain might produce unwanted side effects or even increased seizures.

In context of all of these uncertainties, the study by Rajdev and coworkers is most welcome. These investigators implanted dentate gyrus of hippocampi of rats with recording and stimulating electrodes. When a seizure induced by intraperitoneal kainic acid was detected visually in the electrocardiogram, a 5-second constant-current bipolar train of charge-balanced square waves was delivered to the hippocampus. Stimulation frequency was 5, 60, or 130 pulses per second (pps); pulse width was either 60 or 240 μs; amplitude was 150 or 300 μA. The dependent variables were time for seizure to stop after stimulation, amplitude of local hippocampal field potentials, and intervals between interictal spikes. Without any stimulation, mean seizure duration was 88.7 ± 7.5 seconds, and with stimulation 18.9 to 67.5 seconds. The 5 pps stimuli were most effective at shortening seizures, but 130 pps were most effective in reducing spike amplitude. An upper therapeutic limit was noted, in that pulses of the highest amplitude reduced after-discharge thresholds, which might be expected to facilitate seizures.

Stimulation at 5 pps, most effective in this laboratory study, is very different from the parameters used in hippocampal stimulation clinical trials, with 130 pps (4, 7) or 190 pps (8). Although the differences could be reflective of features specific to the kainic acid model, it must be said that no clinical study has in fact shown that high-frequency stimulation is optimal in epilepsy patients.

We need more studies like this to better define optimal stimulation parameters for clinical neuromodulation, and to close the current gulf between the scanty experimental data and limited clinical experience. Please keep the laboratory studies of neuromodulation coming.

by Robert S. Fisher, MD, PhD

References

Instructions
The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.
   Enter your full name. If you are NOT the main contributing author, please check the box “no” and enter the name of the main contributing author in the space that appears. Provide the requested manuscript information.

2. The work under consideration for publication.
   This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”. Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.
   This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

   Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

   For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Other relationships
   Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.
Section #1 Identifying Information

1. Today’s Date: 12/8/2011

2. First Name Robert Last Name Fisher Degree MD, PhD

3. Are you the Main Assigned Author? ☑ Yes ☐ No

   If no, enter your name as co-author:

4. Manuscript/Article Title: Neurostimulation for epilepsy - do we know the best stimulation parameters?

5. Journal Issue you are submitting for: unknown

Section #2 The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Grant</td>
<td>☑</td>
<td></td>
<td>$600,000.00</td>
<td>Medtronic grant to Stanford University</td>
<td>For being a clinical trial site</td>
</tr>
<tr>
<td>2. Consulting fee or honorarium</td>
<td>☑</td>
<td>$5,000.00</td>
<td></td>
<td>Cyberonics</td>
<td></td>
</tr>
<tr>
<td>3. Support for travel to meetings for the study or other purposes</td>
<td>☑</td>
<td></td>
<td></td>
<td>Medtronic</td>
<td>Travel to FDA and European launch</td>
</tr>
<tr>
<td>4. Fees for participating in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Payment for writing or reviewing the manuscript</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Provision of writing assistance, medicines, equipment, or administrative support.</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Other</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.
** Use this section to provide any needed explanation.
Section #3 Relevant financial activities outside the submitted work.
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type of relationship (in alphabetical order)</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Board membership</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consultancy</td>
<td>☐</td>
<td>&lt;$5000</td>
<td>Cyberonics</td>
<td>vagus nerve stimulation research</td>
<td></td>
</tr>
<tr>
<td>3. Employment</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Expert testimony</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Grants/grants pending</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Payment for lectures including service on speakers bureaus</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Payment for manuscript preparation</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Patents (planned, pending or issued)</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Royalties</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Payment for development of educational presentations</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Stock/stock options</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Travel/accommodations/meeting expenses unrelated to activities listed.**</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Other (err on the side of full disclosure)</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.
** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section #4 Other relationships
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☒ No other relationships/conditions/circumstances that present a potential conflict of interest.
☐ Yes, the following relationships/conditions/circumstances are present:

Thank you for your assistance.
Epilepsy Currents Editorial Board